Lack of immunoglobulins does not prevent C1q binding to RGC and does not alter the progression of experimental glaucoma

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 10, 2012, Pages 6370-6377

  Ding, Qiong J ^a   Cook, Amy C ^a   Dumitrescu, Alina V ^a,b   Kuehn, Markus H ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; IMMUNOGLOBULIN; COMPLEMENT COMPONENT C3; HOMEODOMAIN PROTEIN; RAG 1 PROTEIN; RAG-1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL MEMBRANE; CONTROLLED STUDY; DISEASE COURSE; GLAUCOMA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRAOCULAR PRESSURE ABNORMALITY; MOUSE; NONHUMAN; OPTIC NERVE LESION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; RETINA GANGLION CELL; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; IMMUNE DEFICIENCY; IMMUNOLOGY; INTRAOCULAR PRESSURE; METABOLISM; MOUSE MUTANT; OPTIC NERVE; PATHOLOGY;

ANIMALS; CELLS, CULTURED; COMPLEMENT C1Q; COMPLEMENT C3; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GLAUCOMA; HOMEODOMAIN PROTEINS; IMMUNOGLOBULINS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC DEFICIENCY SYNDROMES; INTRAOCULAR PRESSURE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; OPTIC NERVE; PROTEOMICS; RETINAL GANGLION CELLS;

EID: 84871263827     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10442     Document Type: Article

References (46)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-267.
2. Kuehn MH, Fingert JH, Kwon YH. Retinal ganglion cell death in glaucoma: mechanisms and neuroprotective strategies. Ophthalmol Clin North Am. 2005;18:383-395.
3. Kwon YH, Fingert JH, Kuehn MH, Alward WL. Primary openangle glaucoma. N Engl J Med. 2009;360:1113-1124.
4. Tenner AJ, Fonseca MI. The double-edged flower: roles of complement protein C1q in neurodegenerative diseases. Adv Exp Med Biol. 2006;586:153-176.
5. Vandivier RW, Ogden CA, Fadok VA, et al. Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol. 2002;169:3978-3986.
6. Kuehn MH, Kim CY, Jiang B, Dumitrescu AV, Kwon YH. Disruption of the complement cascade delays retinal ganglion cell death following retinal ischemia-reperfusion. Exp Eye Res. 2008;87:89-95.
7. Rohrer B, Demos C, Frigg R, Grimm C. Classical complement activation and acquired immune response pathways are not essential for retinal degeneration in the rd1 mouse. Exp Eye Res. 2007;84:82-91.
8. Vazquez-Chona F, Song BK, Geisert EE, Jr. Temporal changes in gene expression after injury in the rat retina. Invest Ophthalmol Vis Sci. 2004;45:2737-2746.
9. Bonifati DM, Kishore U. Role of complement in neurodegeneration and neuroinflammation. Mol Immunol. 2007;44:999-1010.
10. Botto M, Dell'Agnola C, Bygrave AE, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet. 1998;19:56-59.
11. Walport MJ. Complement and systemic lupus erythematosus. Arthritis Res. 2002;4Suppl 3:S279-293.
12. Lewis MJ, Botto M. Complement deficiencies in humans and animals: links to autoimmunity. Autoimmunity. 2006;39:367-378.
13. Trouw LA, Blom AM, Gasque P. Role of complement and complement regulators in the removal of apoptotic cells. Mol Immunol. 2008;45:1199-1207.
14. Edelson BT, Stricker TP, Li Z, et al. Novel collectin/C1q receptor mediates mast cell activation and innate immunity. Blood. 2006;107:143-150.
15. Jiang H, Burdick D, Glabe CG, Cotman CW. Tenner AJ. beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J Immunol. 1994;152:5050-5059.
16. Ma W, Rai V, Hudson BI, Song F, Schmidt AM, Barile GR. RAGE binds C1q and enhances C1q-mediated phagocytosis. Cell Immunol. 2012;274:72-82.
17. Kuehn MH, Kim CY, Ostojic J, et al. Retinal synthesis and deposition of complement components induced by ocular hypertension. Exp Eye Res. 2006;83:620-628.
18. Tezel G, Yang X, Luo C, et al. Oxidative stress and the regulation of complement activation in human glaucoma. Invest Ophthalmol Vis Sci. 2010;51:5071-5082.
19. Stasi K, Nagel D, Yang X, et al. Complement component 1Q (C1Q) upregulation in retina of murine, primate, and human glaucomatous eyes. Invest Ophthalmol Vis Sci. 2006;47:1024-1029.
20. Ahmed F, Brown KM, Stephan DA, Morrison JC, Johnson EC, Tomarev SI. Microarray analysis of changes in mRNA levels in the rat retina after experimental elevation of intraocular pressure. Invest Ophthalmol Visual Sci. 2004;45:1247-1258.
21. Howell GR, Macalinao DG, Sousa GL, et al. Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma. J Clin Invest. 2011;121:1429-1444.
22. Boehm N, Wolters D, Thiel U, et al. New insights into autoantibody profiles from immune privileged sites in the eye: a glaucoma study. Brain Behav Immun. 2012;26:96-102.
23. Wax MB. The case for autoimmunity in glaucoma. Exp Eye Res. 2011;93:187-190.
24. Wax M, Yang J, Tezel G. Autoantibodies in glaucoma. Curr Eye Res. 2002;25:113-116.
25. Joachim SC, Reichelt J, Berneiser S, Pfeiffer N, Grus FH. Sera of glaucoma patients show autoantibodies against myelin basic protein and complex autoantibody profiles against human optic nerve antigens. Graefes Arch Clin Exp Ophthalmol. 2008;246:573-580.
26. Laspas P, Gramlich OW, Muller HD, et al. Autoreactive antibodies and loss of retinal ganglion cells in rats induced by immunization with ocular antigens. Invest Ophthalmology Vis Sci. 2011;52:8835-8848.
27. Joachim SC, Wax MB, Seidel P, Pfeiffer N, Grus FH. Enhanced characterization of serum autoantibody reactivity following HSP 60 immunization in a rat model of experimental autoimmune glaucoma. Curr Eye Res. 2010;35:900-908.
28. Wax MB, Tezel G, Yang J, et al. Induced autoimmunity to heat shock proteins elicits glaucomatous loss of retinal ganglion cell neurons via activated T-cell-derived fas-ligand. J Neurosci. 2008;28:12085-12096.
29. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell. 1992;68:869-877.
30. Kim CY, Kuehn MH, Anderson MG, Kwon YH. Intraocular pressure measurement in mice: a comparison between Goldmann and rebound tonometry. Eye. 2006.
31. Sappington RM, Carlson BJ, Crish SD, Calkins DJ. The microbead occlusion model: a paradigm for induced ocular hypertension in rats and mice. Invest Ophthalmol Vis Sci. 2010;51:207-216.
32. Samsel PA, Kisiswa L, Erichsen JT, Cross SD, Morgan JE. A novel method for the induction of experimental glaucoma using magnetic microspheres. Invest Ophthalmol Vis Sci. 2011;52:1671-1675.
33. Chen H, Wei X, Cho KS, et al. Optic neuropathy due to microbead-induced elevated intraocular pressure in the mouse. Invest Ophthalmol Vis Sci. 2011;52:36-44.
34. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
35. Bengtsson B. The variation and covariation of cup and disc diameters. Acta Ophthalmologica. 1976;54:804-818.
36. Wang L, Damji KF, Munger R, et al. Increased disk size in glaucomatous eyes vs normal eyes in the Reykjavik eye study. Am J Ophthalmol. 2003;135:226-228.
37. Yang X, Luo C, Cai J, et al. Neurodegenerative and inflammatory pathway components linked to TNF-alpha/ TNFR1 signaling in the glaucomatous human retina. Invest Ophthalmol Vis Sci. 2011;52:8442-8454.
38. Jiang B, Harper MM, Kecova H, et al. Neuroinflammation in Advanced Canine Glaucoma. Mol Vis. 2010;16:2092-2108.
39. Guo Y, Johnson EC, Cepurna WO, Dyck JA, Doser T, Morrison JC. Early gene expression changes in the retinal ganglion cell layer of a rat glaucoma model. Invest Ophthalmol Vis Sci. 2011;52:1460-1473.
40. Yang Z, Quigley HA, Pease ME, et al. Changes in gene expression in experimental glaucoma and optic nerve transection: the equilibrium between protective and detrimental mechanisms. Invest Ophthalmol Vis Sci. 2007;48: 5539-5548.
41. Streilein JW. Regional immunity and ocular immune privilege. Chem Immunol. 1999;73:11-38.
42. Grus FH, Joachim SC, Bruns K, Lackner KJ, Pfeiffer N, Wax MB. Serum autoantibodies to alpha-fodrin are present in glaucoma patients from Germany and the United States. Invest Ophthalmol Vis Sci. 2006;47:968-976.
43. Tanihara H, Hangai M, Sawaguchi S, et al. Up-regulation of glial fibrillary acidic protein in the retina of primate eyes with experimental glaucoma. Arch Ophthalmol. 1997;115:752-756.
44. Lambris JD. The multifunctional role of C3, the third component of complement. Immunol Today. 1988;9:387-393.
45. Ghannam A, Pernollet M, Fauquert JL, et al. Human C3 deficiency associated with impairments in dendritic cell differentiation, memory B cells, and regulatory T cells. J Immunol. 2008;181:5158-5166.
46. Morohoshi K, Patel N, Ohbayashi M, et al. Serum autoantibody biomarkers for age-related macular degeneration and possible regulators of neovascularization. Exp Mol Pathol. 2012;92:64-73.